Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 03, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Purchased: 800,000 ordinary shares of 25 pence each.
- Purchase Price: 1,300.8286 pence per share.
- Treasury Shares Held: 377,827,158 shares (representing 6.69% of total voting rights).
- Shares in Issue: 5,644,592,690 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through a buyback program. Following the transaction on September 3, 2007, the company's Treasury shareholding increased to 377,827,158 shares. The number of shares in issue remains 5,644,592,690, which serves as the denominator for calculating shareholder notification thresholds under the Financial Services Authority's Disclosure and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Transparency Directive's transitional provision 6.
Investor Verification Checklist
- Verify the total number of shares in issue (5,644,592,690) for accurate calculation of ownership percentages.
- Confirm the updated Treasury share count (377,827,158) and its impact on total voting rights (6.69%).
- Review the specific purchase price (1,300.8286 pence) against market prices on September 3, 2007.
- Note that this filing does not contain financial results; refer to Form 20-F or quarterly reports for revenue and earnings data.